Total Payments
$10,434
2024 Payments
$6,327
Companies
52
Transactions
339
Medicare Patients
25,577
Medicare Billing
$11.4M
Payment Breakdown by Category
Food & Beverage$5,382 (51.6%)
Other$3,657 (35.0%)
Consulting$1,110 (10.6%)
Education$285.77 (2.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $5,382 | 318 | 51.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2,575 | 2 | 24.7% |
| Consulting Fee | $1,110 | 1 | 10.6% |
| Long term medical supply or device loan | $1,082 | 12 | 10.4% |
| Education | $285.77 | 6 | 2.7% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $3,007 | 21 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $1,293 | 25 | $0 (2024) |
| Daiichi Sankyo Inc. | $1,179 | 6 | $0 (2024) |
| Janssen Biotech, Inc. | $599.97 | 44 | $0 (2024) |
| PFIZER INC. | $398.47 | 27 | $0 (2024) |
| Gilead Sciences, Inc. | $324.62 | 15 | $0 (2024) |
| Seagen Inc. | $298.49 | 15 | $0 (2023) |
| Merck Sharp & Dohme LLC | $289.30 | 19 | $0 (2024) |
| Amgen Inc. | $276.76 | 13 | $0 (2022) |
| Lilly USA, LLC | $253.61 | 14 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $6,327 | 88 | AstraZeneca Pharmaceuticals LP ($2,808) |
| 2023 | $1,257 | 66 | Janssen Biotech, Inc. ($117.69) |
| 2022 | $1,011 | 65 | Janssen Biotech, Inc. ($188.24) |
| 2021 | $762.30 | 50 | Janssen Biotech, Inc. ($198.98) |
| 2020 | $366.43 | 17 | Amgen Inc. ($158.31) |
| 2019 | $310.25 | 22 | Merck Sharp & Dohme Corporation ($96.59) |
| 2018 | $272.13 | 21 | Merck Sharp & Dohme Corporation ($53.21) |
| 2017 | $128.06 | 10 | E.R. Squibb & Sons, L.L.C. ($25.67) |
All Payment Transactions
339 individual payment records from CMS Open Payments — Page 1 of 14
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $16.45 | General |
| Category: ONCOLOGY | ||||||
| 12/16/2024 | Janssen Biotech, Inc. | TECVAYLI (Biological), TALVEY, DARZALEX | Food and Beverage | In-kind items and services | $19.11 | General |
| Category: Oncology | ||||||
| 12/12/2024 | GlaxoSmithKline, LLC. | ZEJULA (Drug), JEMPERLI | Food and Beverage | In-kind items and services | $25.26 | General |
| Category: ONCOLOGY | ||||||
| 12/10/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $83.33 | General |
| Category: Oncology | ||||||
| 12/02/2024 | Tempus AI, Inc | XT CDX (Device) | Food and Beverage | In-kind items and services | $13.84 | General |
| Category: NONE | ||||||
| 11/21/2024 | Novartis Pharmaceuticals Corporation | LUTATHERA (Drug) | Food and Beverage | In-kind items and services | $22.72 | General |
| Category: Oncology | ||||||
| 11/21/2024 | Lilly USA, LLC | VERZENIO (Drug), JAYPIRCA | Food and Beverage | In-kind items and services | $14.18 | General |
| Category: Oncology | ||||||
| 11/18/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $22.32 | General |
| 11/15/2024 | Tempus AI, Inc | XT CDX (Device) | Food and Beverage | In-kind items and services | $18.31 | General |
| Category: NONE | ||||||
| 11/14/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $83.33 | General |
| Category: Oncology | ||||||
| 11/11/2024 | Janssen Biotech, Inc. | TECVAYLI (Biological), TALVEY, DARZALEX | Food and Beverage | In-kind items and services | $19.89 | General |
| Category: Oncology | ||||||
| 11/07/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Education | In-kind items and services | $25.95 | General |
| Category: Oncology | ||||||
| 10/31/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $27.24 | General |
| Category: ONCOLOGY | ||||||
| 10/17/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $83.33 | General |
| Category: Oncology | ||||||
| 10/17/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $29.36 | General |
| 10/14/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $25.58 | General |
| Category: ONCOLOGY | ||||||
| 09/30/2024 | Tempus AI, Inc | XT CDX (Device) | Food and Beverage | In-kind items and services | $19.78 | General |
| Category: NONE | ||||||
| 09/27/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $83.33 | General |
| Category: Oncology | ||||||
| 09/26/2024 | PFIZER INC. | BOSULIF (Drug), ELREXFIO, ADCETRIS | Food and Beverage | In-kind items and services | $18.44 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 09/23/2024 | Janssen Biotech, Inc. | TECVAYLI (Biological), TALVEY, DARZALEX | Food and Beverage | In-kind items and services | $19.83 | General |
| Category: Oncology | ||||||
| 09/20/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Education | In-kind items and services | $27.00 | General |
| Category: Oncology | ||||||
| 09/19/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $22.73 | General |
| Category: Hematology | ||||||
| 09/16/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $29.47 | General |
| 09/11/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $14.56 | General |
| Category: Oncology | ||||||
| 09/09/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $23.00 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 69 | 5,314 | 178,418 | $11.8M | $2.6M |
| 2022 | 71 | 5,748 | 208,979 | $10.7M | $2.2M |
| 2021 | 79 | 6,993 | 296,671 | $16.1M | $3.6M |
| 2020 | 86 | 7,522 | 313,451 | $14.7M | $3.0M |
Total Patients
25,577
Total Services
997,519
Medicare Billing
$11.4M
Procedure Codes
305
All Medicare Procedures & Services
305 procedure records from CMS Medicare Utilization — Page 1 of 13
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 28 | 22,800 | $4.3M | $970,254 | 22.6% |
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 2023 | 15 | 12,420 | $2.0M | $473,161 | 23.2% |
| J9299 | Injection, nivolumab, 1 mg | Office | 2023 | 12 | 10,800 | $1.1M | $256,100 | 22.6% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 104 | 14,040 | $987,995 | $252,494 | 25.6% |
| Q5107 | Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg | Office | 2023 | 15 | 5,800 | $643,452 | $131,405 | 20.4% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2023 | 31 | 21,460 | $235,166 | $50,431 | 21.4% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 148 | 538 | $243,709 | $47,200 | 19.4% |
| J1454 | Injection, fosnetupitant 235 mg and palonosetron 0.25 mg | Office | 2023 | 35 | 129 | $210,876 | $44,435 | 21.1% |
| Q5123 | Injection, rituximab-arrx, biosimilar, (riabni), 10 mg | Office | 2023 | 11 | 1,190 | $207,215 | $43,717 | 21.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 342 | 488 | $200,086 | $43,295 | 21.6% |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | Office | 2023 | 15 | 492 | $234,138 | $42,519 | 18.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 135 | 248 | $142,260 | $30,729 | 21.6% |
| J1439 | Injection, ferric carboxymaltose, 1 mg | Office | 2023 | 25 | 30,750 | $118,845 | $26,618 | 22.4% |
| J1437 | Injection, ferric derisomaltose, 10 mg | Office | 2023 | 13 | 1,300 | $103,350 | $20,790 | 20.1% |
| M0010 | Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | Office | 2023 | 46 | 203 | $14,210 | $15,396 | 108.3% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 163 | 735 | $66,871 | $14,581 | 21.8% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 558 | 1,589 | $44,984 | $13,220 | 29.4% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 587 | 1,684 | $45,805 | $12,711 | 27.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 82 | 82 | $57,693 | $12,651 | 21.9% |
| 80048 | Blood test, basic group of blood chemicals (calcium, total) | Office | 2023 | 558 | 1,470 | $43,527 | $12,060 | 27.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 163 | 177 | $51,001 | $11,012 | 21.6% |
| J9041 | Injection, bortezomib, 0.1 mg | Office | 2023 | 11 | 2,625 | $135,185 | $10,763 | 8.0% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 39 | 206 | $52,208 | $9,955 | 19.1% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 84 | 228 | $45,351 | $9,889 | 21.8% |
| 80076 | Liver function blood test panel | Office | 2023 | 476 | 1,239 | $35,435 | $9,835 | 27.8% |
About Dr. Sonia Benn, MD
Dr. Sonia Benn, MD is a Hematology & Oncology healthcare provider based in Southaven, Mississippi. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/02/2006. The National Provider Identifier (NPI) number assigned to this provider is 1801825781.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Sonia Benn, MD has received a total of $10,434 in payments from pharmaceutical and medical device companies, with $6,327 received in 2024. These payments were reported across 339 transactions from 52 companies. The most common payment nature is "Food and Beverage" ($5,382).
As a Medicare-enrolled provider, Benn has provided services to 25,577 Medicare beneficiaries, totaling 997,519 services with total Medicare billing of $11.4M. Data is available for 4 years (2020–2023), covering 305 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology & Oncology
- Location Southaven, MS
- Active Since 07/02/2006
- Last Updated 02/24/2011
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1801825781
Products in Payments
- ENHERTU (Biological) $2,823
- Enhertu (Drug) $1,151
- KISQALI (Drug) $1,134
- IMBRUVICA (Drug) $257.86
- KEYTRUDA (Biological) $245.42
- VENCLEXTA (Drug) $217.89
- NINLARO (Drug) $198.06
- Lenvima (Drug) $168.66
- DARZALEX (Biological) $153.66
- XTANDI (Drug) $138.60
- VERZENIO (Drug) $122.84
- TUKYSA (Drug) $103.45
- ZEJULA (Drug) $102.55
- IBRANCE (Drug) $97.58
- TECVAYLI (Biological) $93.32
- Nerlynx (Drug) $86.19
- XT CDX (Device) $81.03
- JEMPERLI (Biological) $79.83
- ZEPZELCA (Drug) $77.04
- IMFINZI (Biological) $75.16
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.